Crossmark Global Holdings Inc. Sells 32,387 Shares of Genmab A/S (NASDAQ:GMAB)

Crossmark Global Holdings Inc. decreased its holdings in Genmab A/S (NASDAQ:GMAB - Free Report) by 45.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 38,245 shares of the company's stock after selling 32,387 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in Genmab A/S were worth $932,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Russell Investments Group Ltd. increased its holdings in Genmab A/S by 137.7% during the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company's stock worth $28,000 after purchasing an additional 544 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in Genmab A/S during the 1st quarter valued at approximately $43,000. Blue Trust Inc. lifted its position in Genmab A/S by 892.0% during the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company's stock worth $108,000 after acquiring an additional 3,880 shares during the period. Headlands Technologies LLC boosted its holdings in shares of Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company's stock valued at $129,000 after acquiring an additional 4,853 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. raised its position in Genmab A/S by 7.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company's stock valued at $182,000 after acquiring an additional 478 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. HC Wainwright reissued a "buy" rating and set a $50.00 target price on shares of Genmab A/S in a research note on Wednesday, October 16th. Truist Financial dropped their price objective on Genmab A/S from $53.00 to $50.00 and set a "buy" rating for the company in a research note on Monday, September 9th. Redburn Atlantic began coverage on Genmab A/S in a research note on Tuesday, October 8th. They issued a "buy" rating on the stock. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Genmab A/S in a report on Tuesday, August 20th. Finally, BMO Capital Markets reaffirmed an "outperform" rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $45.20.

Genmab A/S Trading Down 2.2 %

NASDAQ GMAB traded down $0.46 during trading hours on Friday, reaching $20.72. 793,747 shares of the company traded hands, compared to its average volume of 699,885. The stock has a market capitalization of $13.71 billion, a PE ratio of 20.03, a PEG ratio of 0.68 and a beta of 0.99. Genmab A/S has a 12 month low of $20.50 and a 12 month high of $32.89. The company has a 50 day moving average of $23.95 and a two-hundred day moving average of $26.24.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). The firm had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same quarter in the prior year, the company posted $0.47 EPS. On average, equities research analysts anticipate that Genmab A/S will post 1.28 earnings per share for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.